Collaborative meta-analysis of randomised trials in chronic lymphocytic leukaemia (CLL)

Collaborative meta-analysis of randomised trials in chronic lymphocytic leukaemia (CLL)

Bibliographic Details
Main Authors:	Binet, J, Dighiero, G, Catovsky, D, Hansen, M, Jaksic, B, Kimby, E, Montserrat, E, Richards, S, Wiernik, P, Grp, C, Cll, F, Grp, D, Sweden, L
Format:	Journal article
Published:	1998

Similar Items

Preliminary results of the UK Medical Research Council trial in chronic lymphocytic leukaemia - CLL3
by: Catovsky, D, et al.
Published: (1998)

Predictors of infection in chronic lymphocytic leukaemia (CLL).
by: Griffiths, H, et al.
Published: (1992)

Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.
by: Catovsky, D, et al.
Published: (2007)

Prognostic factors in chronic lymphocytic leukaemia: the importance of age, sex and response to treatment in survival. A report from the MRC CLL 1 trial. MRC Working Party on Leukaemia in Adults.
by: Catovsky, D, et al.
Published: (1989)

Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials
by: Geisler, C, et al.
Published: (1999)

Patients' experience of chronic lymphocytic leukaemia: baseline health-related quality of life results from the LRF CLL4 trial.
by: Else, M, et al.
Published: (2008)

Comparison of oral and intravenous fludarabine in the LRF CLL4 trial.
by: Hillmen, P, et al.
Published: (2005)

A comparison of the efficacy and safety of oral and intravenous fludarabine in chronic lymphocytic leukemia in the LRF CLL4 trial.
by: Dearden, C, et al.
Published: (2011)

Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group.
by: Richards, S
Published: (1999)

Drug sensitivity by TRAC (DISC) assay as a prognostic factor for patient response in untreated CLL: Results from the UK LRF CLL4 trial.
by: Bosanquet, A, et al.
Published: (2006)

Quality of life in chronic lymphocytic leukemia: 5-year results from the multicenter randomized LRF CLL4 trial.
by: Else, M, et al.
Published: (2012)

The lack of survival differences in randomised trials in CLL may be related to the effect of second line therapies. A report from the LRF CLL4 trial.
by: Catovsky, D, et al.
Published: (2006)

Immunoglobulin replacement in chronic lymphocytic leukaemia.
by: Bunch, C
Published: (1988)

Phase II study of subcutaneous alemtuzumab (Campath-1H) therapy of patients with previously untreated chronic lymphocytic leukemia (CLL).
by: Lundin, J, et al.
Published: (2001)

MicroRNA expression in chronic lymphocytic leukaemia.
by: Lawrie, C, et al.
Published: (2009)

The combination of fludarabine and cyclophosphamide has a beneficial effect on the incidence of hemolytic anemia in chronic lymphocytic leukemia. Results from the UK LRF CLL4 trial
by: Dearden, C, et al.
Published: (2007)

Mutational status of the TP53 gene as a predictor of response and survival in patients with chronic lymphocytic leukemia: results from the LRF CLL4 trial.
by: Gonzalez, D, et al.
Published: (2011)

Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia.
by: Oscier, D, et al.
Published: (2012)

Intravenous immune globulin in chronic lymphocytic leukaemia.
by: Gamm, H, et al.
Published: (1994)

Quality of life in the UK LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Else, M, et al.
Published: (2006)

A comparison of oral and intravenous fludarabine in the LRF CLL4 trial (on behalf of the UKNCRI CLL trials group)
by: Hillmen, P, et al.
Published: (2006)

Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials.
by: CLL Trialists’ Collaborative Group
Published: (2012)

Drug cross-resistance and therapy-induced resistance in chronic lymphocytic leukaemia by an enhanced method of individualised tumour response testing.
by: Bosanquet, A, et al.
Published: (2009)

Response to therapy and survival in CLL is influenced by genetic markers. preliminary analysis from the LRF CLL4 trial.
by: Catovsky, D, et al.
Published: (2004)

The study of DNA methylation anomalies in chronic lymphocytic leukaemia
by: Roy, NBA
Published: (2011)

Quality of life in the LRF CLL4 trial.
by: Else, M, et al.
Published: (2005)

Early results from LRF CLL4: A UK multicenter randomized trial
by: Catovsky, D, et al.
Published: (2005)

Incidence of hemolytic anemia after chemotherapy in the CLL4 trial. A possible protective role for fludarabine plus cyclophosphamide.
by: Catovsky, D, et al.
Published: (2004)

Progressive multifocal leukoencephalopathy as the presenting feature of chronic lymphocytic leukaemia.
by: Bruce, DR, et al.
Published: (2014)

Ofatumumab plus chlorambucil versus chlorambucil alone in patients with untreated chronic lymphocytic leukaemia (CLL): results of the phase III study COMPLEMENT 1 (OMB110911; NCRN-adopted)
by: Hillmen, P, et al.
Published: (2014)

Prognostic factors in the UK LRF CLL4 trial
by: Oscier, D, et al.
Published: (2006)

Chronic granulocytic leukaemia: effect of elective splenectomy on the course of disease.
by: Spiers, A, et al.
Published: (1975)

Baseline characteristics associated with quality of life in CLL patients requiring therapy
by: Else, M, et al.
Published: (2007)

Fludarabine plus cyclophosphamide induces better response rates and progression-free survival across all age and risk groups in the LRF CLL4 trial (on behalf of the UKNCRI CLL Trials Group)
by: Catovsky, D, et al.
Published: (2006)

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia
by: Parker, H, et al.
Published: (2016)

Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL).
by: Lundin, J, et al.
Published: (2002)

Prognostic significance of membrane antigens and morphology in chronic lymphocytic leukemia.
by: Matutes, E, et al.
Published: (1999)

Prognostic factors in the UK LRF CLL4 trial.
by: Oscier, D, et al.
Published: (2006)

Prognostic factors in the UK LRF CLL4 trial.
by: Oscier, D, et al.
Published: (2005)

Fludarabine increases complete response but not survival compared with conventional alkylator-based regimens for previously untreated chronic lymphocytic leukaemia.
by: Richards, S
Published: (2005)